Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Muñoz, E.
Right arrow Articles by Tolosa, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muñoz, E.
Right arrow Articles by Tolosa, E.
Neurology 1999;52:297
© 1999 American Academy of Neurology
Articles

{alpha}1-Antichymotrypsin gene polymorphism and susceptibility to Parkinson’s disease

E. Muñoz, MD, V. Obach, MD, R. Oliva, MD, M. J. Martí, MD, M. Ezquerra, PhD, P. Pastor, MD, F. Ballesta, MD and E. Tolosa, MD

From the Neurology Service (Drs. Muñoz, Obach, Martí, Pastor, and Tolosa) and Genetic Service (Drs. Oliva, Ezquerra, and Ballesta), Institut d’Investigaciones Biomèdiques August Pi i Sunyer, Hospital Clínic i Universitari, University of Barcelona, Spain.

Address correspondence and reprint requests to Dr. Rafael Oliva, Hospital Clínic de Barcelona Villarroel, 170, 08036 Barcelona, Spain; e-mail: oliva{at}medicina.ub.es

OBJECTIVE: To determine whether the {alpha}1-antichymotrypsin AA genotype (ACT-AA) confers susceptibility for developing Parkinson’s disease (PD) in the Spanish population.

BACKGROUND: A correlation between the ACT-AA genotype and the risk of developing PD has been recently reported in the Japanese population.

METHODS: The ACT genotypes of 71 patients diagnosed with clinically definite PD were compared with those of 109 age-matched healthy control subjects.

RESULTS: The authors found that the ACT-AA polymorphism frequency was not increased significantly in the PD group (31%) compared with the control group (28.4%). The ACT allelic distribution was also similar for familial and sporadic PD, for female and male patients, and for the different clinical subtypes of PD. The age at onset of PD was significantly lower in the ACT-AA patients compared with non-ACT-AA patients. When the actual age was considered, the ACT-AA frequency was higher in PD patients <=50 years old (50%) compared with that present in patients >50 years old (26.8%), but the same effect was found in control subjects.

CONCLUSIONS: The ACT-AA polymorphism is not related to an increased risk of developing PD in the Spanish population. The ACT-AA overrepresentation in PD and control subjects <=50 years old suggests that this polymorphism could be associated with life-threatening conditions other than PD.




This article has been cited by other articles:


Home page
 IOVSHome page
B. J. Fan, D. Y. Wang, C. C. Y. Tham, D. S. C. Lam, and C. P. Pang
Gene Expression Profiles of Human Trabecular Meshwork Cells Induced by Triamcinolone and Dexamethasone
Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 1886 - 1897.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
V. Obach, M. Revilla, N. Vila, A. Cervera, and A. Chamorro
{alpha}1-Antichymotrypsin Polymorphism: A Risk Factor for Hemorrhagic Stroke in Normotensive Subjects
Stroke, November 1, 2001; 32(11): 2588 - 2591.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
N. Vila, V. Obach, M. Revilla, R. Oliva, and A. Chamorro
{alpha}1-Antichymotrypsin Gene Polymorphism in Patients With Stroke
Stroke, September 1, 2000; 31(9): 2103 - 2105.
[Abstract] [Full Text] [PDF]